Abstract 252P
Background
Uterine sarcomas (US) are a rare, heterogeneous group of malignancies that have rapid progressive clinical course and poor prognosis. We are reporting a retrospective review of clinico-pathological characteristics and outcome of therapy of these tumors in Qatar.
Methods
Retrospective records of 37 patients with US treated in Qatar between January 2010 and December 2016 were reviewed. They were stratified according to the age at diagnosis, menopausal status, ethnic group, pathological subtype of the tumor, grade, stage and treatment modalities (single vs combined modalities; surgical procedure, radiotherapy treatment, adjuvant and palliative chemotherapy. Diagnostic and pathology work was done in one facility. Treatment plan was discussed in MDT. The surgical treatment options were TAH with our without BSO. The chemotherapy we used is Docetaxel Gemcitabine in adjuvant setting as well as palliative treatment for metastatic cases. Radiotherapy was conducted via external beam irradiation followed by brachytherapy. Overall survival (OS) was obtained from the date of diagnosis to the date of death. For the patients who were alive, data was censored on the date of last follow up visit.
Results
For the reviewed 37 patients, the range of age was 23-64 years old with median age 47 years. LMS are representing the most frequent subtype seen in 15 patients (40%), ESS- 10 (28%), RMS 6 (16%), MMMT 2 (4 %) and non-specified 4 (12%). The stage of the disease at time of diagnosis was 1 in 26%, stage II in 48%, stage III in 11% and stage IV 15%. Total 23 patients underwent surgical resection, 12 patients (53%) simple hysterectomy and 11 (47%) TAH+BSO with LN dissection. 13 patients receivedchemotherapy, in 7 cases as adjuvant, in 4 combined with radiotherapy and in 2 cases as palliative. 13 patient received radiotherapy and brachytherapy. Median follow up time was 42 months. Thorough the time 10 patients died, 18 are still alive and 9 have lost follow up. The Kaplan Maier Curve showed median OS 40 months. Survival rate after one year was 79% and after 3 years 58%.
Conclusions
In this pattern of population where the majority of US presented in early stages (74%), 42% will die within the first 3 years which reflect the need for running big phase 3 trials for optimization of the treatment approaches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ashraf Fadlelseid.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - Clinical verification on the relationship between serum lipid metabolism and the immune microenvironment in breast cancer patients
Presenter: Wataru Goto
Session: Poster display session
Resources:
Abstract
42P - Genome wide copy number analysis of circulating tumour cells in breast cancer liver metastasis
Presenter: Saber Imani
Session: Poster display session
Resources:
Abstract
43P - A hotspot variants p.H1047R and p.H1047L in p110α/ΔNp63α complex affects structure, function and contributes to susceptibility metastatic breast cancer
Presenter: Zou Linglin
Session: Poster display session
Resources:
Abstract
44P - Correlation of circulating tumour cells with PET-CT in metastatic breast cancer
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract
45P - The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumour location
Presenter: Hubert Beaumont
Session: Poster display session
Resources:
Abstract
46P - Plasma soluble CD36 of breast cancer based on pathological and clinical characteristics
Presenter: Aditia Romadhoni
Session: Poster display session
Resources:
Abstract
47P - Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer
Presenter: MAYUKO MIKI
Session: Poster display session
Resources:
Abstract
48P - Development of MDA-MB-231-3D-Spheroid as a reliable model for studying Nav1.5 and nNav1.5-mediated breast cancer metastasis
Presenter: Ahmad Murtadha
Session: Poster display session
Resources:
Abstract
49P - Biochemical study on modifying role of variants of leptin gene and its receptor on serum leptin levels in breast cancer
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
50P - Prognostic factors of recurrence or distant metastasis in elderly breast cancer patients
Presenter: Seungju Lee
Session: Poster display session
Resources:
Abstract